Lutetium Lu-177 vipivotide tetraxetan
- Generic Name
- Lutetium Lu-177 vipivotide tetraxetan
- Brand Names
- Pluvicto
- Drug Type
- Small Molecule
- Chemical Formula
- C49H68LuN9O16
- CAS Number
- 1703749-62-5
- Unique Ingredient Identifier
- G6UF363ECX
- Background
Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
...
- Indication
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 80
- Registration Number
- NCT06461689
- Locations
- 🇫🇷
CHRU de NANCY, Vandoeuvre les Nancy cedex, France
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 200
- Registration Number
- NCT06449781
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Rohan Garje
- Target Recruit Count
- 30
- Registration Number
- NCT06329830
- Locations
- 🇺🇸
Miami Cancer Institute, Miami, Florida, United States
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT06303713
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 32
- Registration Number
- NCT06199453
- Locations
- 🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 48
- Registration Number
- NCT05766371
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 44
- Registration Number
- NCT05340374
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
EBRT + Lu-PSMA for N1M0 Prostate Cancer
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT05162573
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-12-15
- Target Recruit Count
- 93
- Registration Number
- NCT05150236
- Locations
- 🇦🇺
Royal Brisbane and Womens hospital, Herston, Queensland, Australia
🇦🇺Sir Charles Gairdner, Nedlands, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05079698
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.